source
- Sanofi eyes late-stage and commercial acquisitions to counter upcoming Dupixent revenue dropSanofi said on its third‑quarter earnings call that it is looking to acquire late‑stage and commercial medicines to sustain growth after Dupixent loses exclusivity. CEO Belén Garijo highlighted th…
- Setara Biosciences raises $90 million Series A to advance Jazz-spun rare disease programsSetara Biosciences has been created to focus on a set of rare-disease assets that Jazz Pharmaceuticals retained after acquiring Actio Biosciences. The new company secured $90 million in Series A f…